Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prelude Therapeutics (PRLD) EBITDA (2024 - 2026)

Prelude Therapeutics' EBITDA history spans 3 years, with the latest figure at -$10.4 million for Q1 2026.

  • On a quarterly basis, EBITDA rose 67.5% to -$10.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$77.9 million, a 38.98% increase, with the full-year FY2025 number at -$99.5 million, up 21.86% from a year prior.
  • EBITDA hit -$10.4 million in Q1 2026 for Prelude Therapeutics, up from -$16.5 million in the prior quarter.
  • Over the last five years, EBITDA for PRLD hit a ceiling of -$10.4 million in Q1 2026 and a floor of -$34.8 million in Q2 2024.
  • Historically, EBITDA has averaged -$26.4 million across 3 years, with a median of -$31.2 million in 2025.
  • Biggest five-year swings in EBITDA: fell 0.69% in 2025 and later soared 67.5% in 2026.
  • Tracing PRLD's EBITDA over 3 years: stood at -$28.9 million in 2024, then skyrocketed by 43.0% to -$16.5 million in 2025, then soared by 36.58% to -$10.4 million in 2026.
  • Business Quant data shows EBITDA for PRLD at -$10.4 million in Q1 2026, -$16.5 million in Q4 2025, and -$19.7 million in Q3 2025.